Treace Medical Concepts (NASDAQ:TMCI) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Treace Medical Concepts (NASDAQ:TMCI) released its quarterly earnings data on Friday. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.06, FiscalAI reports. Treace Medical Concepts had a negative return on equity of 67.04% and a negative net margin of 29.44%.The firm had revenue of $45.38 million during the quarter, compared to the consensus estimate of $44.02 million.

Here are the key takeaways from Treace Medical Concepts’ conference call:

• Case volume growth accelerated to high single digits year over year in Q2, supported by market-share gains and broader adoption of Treace’s new bunion systems. Approximately 40% of Lapiplasty surgeons have now used at least one of the three systems launched in 2025.
• Treace raised its 2026 revenue guidance to $204 million-$212 million, up from a prior range of $202 million-$212 million, and expects revenue to return to positive growth in the seasonally strong fourth quarter.
• Profitability and cash trends improved, with Q2 adjusted EBITDA loss narrowing slightly to $3.5 million, operating expenses falling 8%, and year-to-date cash usage declining 57%. Full-year adjusted EBITDA guidance was improved to a loss of $3 million-$5 million.
• The company is expanding beyond bunion procedures through SuperBite, HyperPlate XM, GreatReleaseXM, and planned CartiBlaster launches, which management estimates could expand its U.S. addressable market by approximately $300 million.
• Q2 revenue fell 4% to $45.4 million, pressured by lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products. Management expects the associated average selling price headwind to persist through Q3.

Treace Medical Concepts Stock Up 8.7%

Shares of TMCI traded up $0.38 during midday trading on Friday, hitting $4.76. 880,000 shares of the company’s stock traded hands, compared to its average volume of 767,200. The company has a current ratio of 3.58, a quick ratio of 2.53 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $308.78 million, a price-to-earnings ratio of -4.91 and a beta of 1.37. Treace Medical Concepts has a 1 year low of $1.17 and a 1 year high of $7.78. The firm’s fifty day moving average is $4.15 and its 200-day moving average is $2.73.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Truist Financial upped their price target on shares of Treace Medical Concepts from $2.00 to $4.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Wall Street Zen raised shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Weiss Ratings raised shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $4.97.

Insiders Place Their Bets

In related news, CEO John T. Treace acquired 22,887 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were purchased at an average price of $4.04 per share, for a total transaction of $92,463.48. Following the completion of the acquisition, the chief executive officer directly owned 7,376,150 shares in the company, valued at $29,799,646. The trade was a 0.31% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought a total of 371,600 shares of company stock valued at $1,104,801 over the last three months. 23.42% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. lifted its position in shares of Treace Medical Concepts by 18.6% during the 2nd quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock valued at $88,000 after buying an additional 2,362 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock valued at $28,000 after purchasing an additional 3,674 shares in the last quarter. Parkman Healthcare Partners LLC grew its position in shares of Treace Medical Concepts by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 847,675 shares of the company’s stock valued at $5,688,000 after purchasing an additional 3,677 shares during the period. Barclays PLC increased its stake in shares of Treace Medical Concepts by 7.4% during the fourth quarter. Barclays PLC now owns 87,664 shares of the company’s stock worth $215,000 after purchasing an additional 6,077 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of Treace Medical Concepts by 5.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 162,976 shares of the company’s stock worth $958,000 after purchasing an additional 7,898 shares during the last quarter. Hedge funds and other institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.